|
PUS7L expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62447832963153E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.1094237467878E-14 |
| Normal-vs-Stage2 |
1.7979999711315E-09 |
| Normal-vs-Stage3 |
5.55111512312578E-16 |
| Normal-vs-Stage4 |
1.62525548574877E-12 |
| Stage1-vs-Stage2 |
6.810800E-01 |
| Stage1-vs-Stage3 |
4.238300E-02 |
| Stage1-vs-Stage4 |
2.436600E-04 |
| Stage2-vs-Stage3 |
2.959200E-01 |
| Stage2-vs-Stage4 |
2.524300E-02 |
| Stage3-vs-Stage4 |
1.226650E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.11022302462516E-16 |
| Normal-vs-AfricanAmerican |
2.02149999994905E-06 |
| Normal-vs-Asian |
2.88399970571618E-10 |
| Caucasian-vs-AfricanAmerican |
6.384000E-01 |
| Caucasian-vs-Asian |
8.982800E-01 |
| AfricanAmerican-vs-Asian |
7.174000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
<1E-12 |
| Normal-vs-Female |
1.62458935193399E-12 |
| Male-vs-Female |
4.065600E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.65245594985208E-12 |
| Normal-vs-Age(41-60Yrs) |
9.99200722162641E-16 |
| Normal-vs-Age(61-80Yrs) |
1.74349423787135E-12 |
| Normal-vs-Age(81-100Yrs) |
4.411600E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.427960E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.910000E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
5.880200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
8.191800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.659600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.927600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.353600E-02 |
| Classical-VS-Follicular |
9.158200E-01 |
| Classical-VS-Other |
2.374000E-01 |
| Classical-VS-Normal |
2.28429497539651E-11 |
| Tall-VS-Follicular |
6.051700E-02 |
| Tall-VS-Other |
9.838600E-01 |
| Tall-VS-Normal |
1.31050725826753E-12 |
| Follicular-VS-Other |
4.344200E-01 |
| Follicular-VS-Normal |
7.40170003066254E-09 |
| Other-VS-Normal |
1.588600E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.11022302462516E-16 |
| Normal-vs-N1 |
1.70974345792274E-14 |
| N0-vs-N1 |
3.716300E-02 |
|
|
